Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
NYSE:JNJ
Price:
234
USD
1.41%
Market Closed
Market Cap:
$563.8B
Relative Value
The Relative Value of one
JNJ
stock under the Base Case scenario is
171.49
USD.
Compared to the current market price of 234 USD,
Johnson & Johnson
is
Overvalued by 27%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JNJ
Relative Value
Base Case
171.49
USD
Overvaluation 27%
Multiples Across Competitors
JNJ Competitors Multiples
Johnson & Johnson Competitors
Johnson & Johnson Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563B USD | 6 | 21 | 14.6 | 17.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
948.8B USD | 16 | 51.5 | 34.6 | 37.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF | 4.7 | 30.6 | 12.9 | 15 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.6B GBP | 5.1 | 31.6 | 15.1 | 22.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.1B USD | 4.5 | 15.1 | 10.7 | 12.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
224.1B CHF | 5.2 | 20.1 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.4 | 9.3 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD | 2.3 | 14.9 | 7.6 | 10.3 | |
| FR |
|
Sanofi SA
PAR:SAN
|
98.2B EUR | 1.7 | 8.3 | 7.7 | 7.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
114.1B USD | 2.4 | 18.9 | 6.8 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
